Beş yıllık rotavirüs aşı sonuçlarımız

Yıl 2013, Cilt: 19 Sayı: 2, 86 - 87, 01.03.2013

Hamza Yazgan Yazgan2 Zerrin Esengül Keleş Arzu Gebeşçe Mehmet Demirdöven

https://doi.org/10.5455/GMJ-30-2013-125

Öz

We aimed to evaluate the results of 5 years of rotavirus vaccination experience and compare the effects of monovalent and pentavalent vaccines. This retrospective study included 2345 children vaccinated in a trial that was held between January 2007 and January 2012. Information was obtained on whether the patient was administered the monovalent or pentavalent vaccine, whether he/she had rotavirus gastroenteritis after the vaccination, and whether he/she was treated as an outpatient or an inpatient. This information was obtained from the computer records and, in cases where information was lacking, the families were called to obtain missing details. In all patients with complaints of diarrhea, rotavirus antigen analysis was done with a rapid immunochromatographic stool test. The age range of the children was 3–60 months. Of the patients included in the study, 1270 (54%) were female and 1075 (46%) male. The monovalent vaccine was administered to 1700 (72.5%) children, while the pentavalent vaccine was administered to 645 (27.5%) children. After administration of the vaccine, no major complications were reported. Symptomatic rotavirus gastroenteritis was detected in 4 % of vaccinated children. No patients died due to rotavirus infection. There was no statistically significant difference between the vaccines in terms of the incidence of rotavirus gastroenteritis and the number of children who were hospitalized or received outpatient treatment (P > 0.05). Symptomatic rotavirus gastroenteritis was detected in only 4 % of the vaccinated children in our study. Moreover, there is no significant difference in the protection offered by the monovalent and pentavalent vaccines.

Anahtar Kelimeler

Monovalent vaccine; pentavalent vaccine; rotavirus; rotavirus vaccine.

Our results for five years of rotavirus vaccination

Öz

Beş yıldır uyguladığımız rotavirüs aşısı sonuçlarını değerlendirmeyi ve pentavalan ile ve monovalan aşının etkinliğini karşılaştırmayı amaçladık. Ocak 2007– Ocak 2012 arasında rotavirus aşısı yapılan 2345 çocuk çalışmaya alındı. Hasta verileri bilgisayar kayıtlarından elde edildi. Bilgilerine ulaşılamayan çocukların aileleri telefonla arandı. Çalışmada rotavirüs gastroenteriti olup olmadığı, olduysa tedavinin şekli (ayaktan veya yatarak) ve hangi aşının uygulandığı (monovalan veya pentavalan) sorgulandı. Tanı için gaitada rotavirüs antijeni (rapid immunochromatographic test) bakıldı. İki aşı; rotavirüs gastroenteritine yakalanma ve ağır gastroenterit (hastanede tedavi) geçirme durumuna göre karşılaştırıldı. Veriler SPSS 15,0 istatistik program kullanılarak değerlendirildi. P

Anahtar Kelimeler

Monovalan aşı; pentavalan aşı; rotavirüs; rotavirüs aşısı.

Kaynakça

• 1. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12(2):304-6. 2. WHO. Rotavirus vaccines. Wkyl Epidemiol Rec 2007; 82:285- 95.
• 3. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006;25(1 Suppl):S7-11.
• 4. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011;30(1 Suppl):S1-5.
• 5. Bernstein DI. Rotavirus overview. Pediatr Infect Dis J 2009;28(3 Suppl):S50-3.
• 6. Biçer S, Şahin GT, Koncay B. Çocuk acil servisinde saptanan rotavirüs gastroenteriti olgularının sıklığı. Çocuk Enfeksiyon Derg 2008;2(3):96-9.
• 7. Elliott EJ. Acute gastroenteritis in children. BMJ 2007;334(7583):35-40.
• 8. Kurugöl Z, Geylani S, Karaca Y, Umay F, Erensoy S, Vardar F, et al. Rotavirus gastroenteritis among children under five years of age in Izmir, Turkey. Turk J Pediatr 2003;45(4):290-4.
• 9. Berk E, Kayman T. Akut gastroenteritli çocuk hastalarda rotavirus sıklığı. ANKEM Derg 2011;25(2):103-6.
• 10. Senturia YD, Peckham CS, Cordery M, Chrystie IA, Banatvala JE, Andre FE. Live attenuated oral rotavirus vaccine. Lancet 1987;2(8567):1091-2.
• 11. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007;119(1):171-82.
• 12. Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009; 28(2):345-51.
• 13. Churgay CA, Aftab Z. Gastroenteritis in children: Part II. Prevention and Management. Am Fam Physician. 2012;85(11):1066–70.
• 14. Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother. 2012;8(10):1407-15.
• 15. Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006;24(2):4821-9.
• 16. Grant LR, Watt JP, Weatherholtz RC, Moulton LH, Reid R, Santosham M, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatr Infect Dis J 2012;31(2):184-8.